PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Daniel Gaudet, Robert C. Scott et al.|The Lancet|2014Cited by 750
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trialVanita R. Aroda, J. Hans DeVries, Stephen C. Bain et al.|The Lancet Diabetes & Endocrinology|2017Cited by 439
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 TrialBernard Zinman, Kuninobu Takai, Vanita R. Aroda et al.|Diabetes Care|2019Cited by 282
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trialsVanita R. Aroda, Ildiko Lingvay, Andrew Ahmann et al.|Diabetes & Metabolism|2019Cited by 281
Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice GuidelineConnie B. Newman, Lisa R. Tannock, Michael J. Blaha et al.|The Journal of Clinical Endocrinology & Metabolism|2020Cited by 147